Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'IRBESARTAN' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 106 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Taylor, AA
      Is there a place for combining angiotensin-converting enzyme inhibitors and angiotensin-receptor antagonists in the treatment of hypertension, renal disease or congestive heart failure?

      CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
    2. Muniz, P; Fortuno, A; Zalba, G; Fortuno, MA; Diez, J
      Effects of loop diuretics on angiotensin II-stimulated vascular smooth muscle cell growth

      NEPHROLOGY DIALYSIS TRANSPLANTATION
    3. Meredith, P; Trenkwalder, P
      Angiotensin II antagonists for hypertension: There are differences in efficacy

      AMERICAN JOURNAL OF HYPERTENSION
    4. Hansson, L
      The relationship between dose and antihypertensive effect for different AT(1)-receptor blockers

      BLOOD PRESSURE
    5. Waeber, B
      Achieving blood pressure targets in the management of hypertension

      BLOOD PRESSURE
    6. Belz, GG
      Pharmacological differences among angiotensin II receptor antagonists

      BLOOD PRESSURE
    7. Mancia, G
      Clinical differences among angiotensin II receptor antagonists

      BLOOD PRESSURE
    8. Parving, HH
      Hypertension and diabetes: the scope of the problem

      BLOOD PRESSURE
    9. Li, Q; Pfaffendorf, M; van Zwieten, PA
      Different types of antagonism by losartan and irbesartan on the effects ofangiotensin II and its degradation products in rabbit arteries

      FUNDAMENTAL & CLINICAL PHARMACOLOGY
    10. Mounier-Vehier, C; Devos, P
      Angiotensin II receptor antagonists: are they all the same?

      PRESSE MEDICALE
    11. Stokes, GS; Monaghan, JC; Ryan, M; Woodward, M
      Efficacy of an angiotensin II receptor antagonist in managing hyperaldosteronism

      JOURNAL OF HYPERTENSION
    12. Malmqvist, K; Kahan, T; Edner, M; Held, C; Hagg, A; Lind, L; Muller-Brunotte, R; Nystrom, F; Ohman, KP; Osbakken, MD; Ostergren, J
      Regression of left ventricular hypertrophy in human hypertension with irbesartan

      JOURNAL OF HYPERTENSION
    13. Touyz, RM; He, G; El Mabrouk, M; Diep, Q; Mardigyan, V; Schiffrin, EL
      Differential activation of extracellular signal-regulated protein kinase 1/2 and p38 mitogen activated-protein kinase by AT(1) receptors in vascular smooth muscle cells from Wistar-Kyoto rats and spontaneously hypertensive rats

      JOURNAL OF HYPERTENSION
    14. Balt, JC; Mathy, MJ; Pfaffendorf, M; van Zwieten, PA
      Inhibition of facilitation of sympathetic neurotransmission and angiotensin II-induced pressor effects in the pithed rat: comparison between valsartan, candesartan, eprosartan and embusartan

      JOURNAL OF HYPERTENSION
    15. Wurzner, G; Gerster, JC; Chiolero, A; Maillard, M; Fallab-Stubi, CL; Brunner, HR; Burnier, M
      Comparative effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia and gout

      JOURNAL OF HYPERTENSION
    16. Henriksen, EJ; Jacob, S; Kinnick, TR; Teachey, MK; Krekler, M
      Selective angiotensin II receptor antagonism reduces insulin resistance inobese Zucker rats

      HYPERTENSION
    17. Leenen, FHH; Yuan, BX
      Prevention of hypertension by irbesartan in Dahl S rats relates to centralangiotensin II type 1 receptor blockade

      HYPERTENSION
    18. Coats, AJS
      Angiotensin Receptor Blockers - finally the evidence is coming in: IDNT and RENAAL

      INTERNATIONAL JOURNAL OF CARDIOLOGY
    19. Dol, F; Martin, G; Staels, B; Mares, AM; Cazaubon, C; Nisato, D; Bidouard, JP; Janiak, P; Schaeffer, P; Herbert, JM
      Angiotensin AT(1) receptor antagonist irbesartan decreases lesion size, chemokine expression, and macrophage accumulation in apolipoprotein E-deficient mice

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    20. Balt, JC; Mathy, MJ; Nap, A; Pfaffendorf, M; van Zwieten, PA
      Effect of the AT(1)-receptor antagonists losartan, irbesartan, and telmisartan on angiotensin II-induced facilitation of sympathetic neurotransmission in the rat mesenteric artery

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    21. Ribstein, J; Picard, A; Armagnac, C; Sissmann, J; Mimran, A
      Inhibition of the acute effects of angiotensin II by the receptor antagonist irbesartan in normotensive men

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    22. Khanina, NY; Ektova, TV; Upnitsky, AA; Belousov, YB
      Effect of long-term therapy with irbesartan and enalapril on diastolic left ventricular function in patients with chronic heart failure

      KARDIOLOGIYA
    23. Gohlke, P; Weiss, S; Jansen, A; Wienen, W; Stangier, J; Rascher, W; Culman, J; Unger, T
      AT(1) receptor antagonist telmisartan administered peripherally inhibits central responses to angiotensin II in conscious rats

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    24. Bonnet, F; Cooper, ME; Kawachi, H; Allen, TJ; Boner, G; Cao, Z
      Irbesartan normalises the deficiency in glomerular nephrin expression in amodel of diabetes and hypertension

      DIABETOLOGIA
    25. Waeber, B
      A review of irbesartan in anti hypertensive therapy: Comparison with otheranti hypertensive agents

      CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
    26. Dalla Libera, L; Ravara, B; Angelini, A; Rossini, K; Sandri, M; Thiene, G; Ambrosio, GB; Vescovo, G
      Beneficial effects on skeletal muscle of the angiotensin II type 1 receptor blocker irbesartan in experimental heart failure

      CIRCULATION
    27. Vauquelin, G; Morsing, P; Fierens, FLP; De Backer, JP; Vanderheyden, PML
      A two-state receptor model for the interaction between angiotensin II type1 receptors and non-peptide antagonists

      BIOCHEMICAL PHARMACOLOGY
    28. Hansson, L; Ruilope, LM
      Reaching BP targets: physicians' flexibility with therapy - Based on a satellite symposium held at the XXIst Congress of the European Society of Cardiology, Barcelona, Spain, 28 August 1999 - Foreword

      EUROPEAN HEART JOURNAL SUPPLEMENTS
    29. Waeber, B
      Blood pressure control: a review on irbesartan

      EUROPEAN HEART JOURNAL SUPPLEMENTS
    30. Belz, GG; in't Veld, AJM
      Differences among angiotensin II receptor antagonists: choosing the optimal agent in clinical practice

      EUROPEAN HEART JOURNAL SUPPLEMENTS
    31. Dina, R; Jafari, M
      Angiotensin II-receptor antagonists: An overview

      AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY
    32. Gansevoort, RT; de Zeeuw, D
      The antihypertensive and renal effects of angiotensin II receptor antagonists: remaining questions

      CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION
    33. Benetos, A; Gautier, S; Lafleche, A; Topouchian, J; Frangin, G; Girerd, X; Sissmann, J; Safar, ME
      Blockade of angiotensin II type 1 receptors: Effect on carotid and radial artery structure and function in hypertensive humans

      JOURNAL OF VASCULAR RESEARCH
    34. Israili, ZH
      Clinical pharmacokinetics of angiotensin II (AT(1)) receptor blockers in hypertension

      JOURNAL OF HUMAN HYPERTENSION
    35. Makris, TK; Stavroulakis, GA; Krespi, PG; Hatzizacharias, AN; Triposkiadis, FK; Tsoukala, CG; Votteas, VV; Kyriakidis, MK
      Fibrinolytic/hemostatic variables in arterial hypertension: Response to treatment with irbesartan or atenolol

      AMERICAN JOURNAL OF HYPERTENSION
    36. Schmermund, A; Lerman, LO; Rumberger, JA; Lund, PE; Pfeifer, EA; Sheedy, PF; Ritman, EL
      Effects of acute and chronic angiotensin receptor blockade on myocardial vascular blood volume and perfusion in a pig model of coronary microembolization

      AMERICAN JOURNAL OF HYPERTENSION
    37. Oparil, S
      Newly emerging pharmacologic differences in angiotensin II receptor blockers

      AMERICAN JOURNAL OF HYPERTENSION
    38. Gavras, H
      Update on the clinical pharmacology of candesartan cilexetil

      AMERICAN JOURNAL OF HYPERTENSION
    39. Descombes, E; Fellay, G
      End-stage renal failure after irbesartan prescription in a diabetic patient with previously stable chronic renal insufficiency

      RENAL FAILURE
    40. Unger, T
      Differences among angiotensin II type 1 receptor blockers: Characteristicsof candesartan cilexetil

      BLOOD PRESSURE
    41. von Vigier, RO; Zberg, PM; Teuffel, O; Bianchetti, MG
      Preliminary experience with the angiotensin II receptor antagonist irbesartan in chronic kidney disease

      EUROPEAN JOURNAL OF PEDIATRICS
    42. Preckel, B; Schlack, W; Gonzalez, M; Obal, D; Barthel, H; Thamer, V
      Influence of the angiotensin II AT(1) receptor antagonist irbesartan on isehemia/reperfusion injury in the dog heart

      BASIC RESEARCH IN CARDIOLOGY
    43. Song, JC; White, CM
      Pharmacologic, pharmacokinetic, and therapeutic differences among angiotensin II receptor antagonists

      PHARMACOTHERAPY
    44. Asmar, P; Lacourciere, Y
      A new approach to assessing antihypertensive therapy: effect of treatment on pulse pressure

      JOURNAL OF HYPERTENSION
    45. Petkun, W
      AT(1)-receptor blockers

      EUROPEAN HEART JOURNAL
    46. Fabiani, ME; Dinh, DT; Nassis, L; Casley, DJ; Johnston, CI
      Comparative in vivo effects of irbesartan and losartan on angiotensin II receptor binding in the rat kidney following oral administration

      CLINICAL SCIENCE
    47. Belousov, YB
      Clinical efficacy and safety of irbesartan in patients with mild and moderate hypertension. Results of a multicenter study

      KARDIOLOGIYA
    48. Malacco, E; Piazza, S; Meroni, R; Milanesi, A
      Comparison of valsartan and irbesartan in the treatment of mild to moderate hypertension: A randomized, open-label, crossover study

      CURRENT THERAPEUTIC RESEARCH-CLINICAL AND EXPERIMENTAL
    49. Gonzalez, L; Alonso, RM; Jimenez, RM
      A high-performance liquid chromatographic method for screening angiotensinII receptor antagonists in human urine

      CHROMATOGRAPHIA
    50. Nishimura, Y; Ito, T; Hoe, KL; Saavedra, JM
      Chronic peripheral administration of the angiotensin II AT(1) receptor antagonist Candesartan blocks brain AT(1) receptors

      BRAIN RESEARCH
    51. Vanderheyden, PML; Fierens, FLP; Vauquelin, G
      Angiotensin II type 1 receptor antagonists - Why do some of them produce insurmountable inhibition?

      BIOCHEMICAL PHARMACOLOGY
    52. Vanderheyden, PML; Fierens, FLP; De Backer, JP; Vauquelin, G
      Reversible and syntopic interaction between angiotensin receptor antagonists on Chinese hamster ovary cells expressing human angiotensin II type I receptors

      BIOCHEMICAL PHARMACOLOGY
    53. Littlejohn, T; Saini, R; Kassler-Taub, K; Crysant, SG; Marbury, T
      Long-term safety and antihypertensive efficacy of irbesartan: Pooled results of five open-label studies

      CLINICAL AND EXPERIMENTAL HYPERTENSION
    54. Howe, P; Phillips, P; Saini, R; Kassler-Taub, K
      The antihypertensive efficacy of the combination of irbesartan and hydrochlorothiazide assessed by 24-hour ambulatory blood pressure monitoring

      CLINICAL AND EXPERIMENTAL HYPERTENSION
    55. Mimran, A; Ribstein, J; DuCailar, G
      Angiotensin II receptor antagonists and hypertension

      CLINICAL AND EXPERIMENTAL HYPERTENSION
    56. Messerli, FH
      ... And losartan was no better than placebo

      JOURNAL OF HUMAN HYPERTENSION
    57. Raskin, P; Guthrie, R; Flack, JM; Reeves, RA; Saini, R
      The long-term antihypertensive activity and tolerability of irbesartan with hydrochlorothiazide

      JOURNAL OF HUMAN HYPERTENSION
    58. Kochar, M; Guthrie, R; Triscari, J; Kassler-Taub, K; Reeves, RA
      Matrix study of irbesartan with hydrochlorothiazide in mild-to-moderate hypertension

      AMERICAN JOURNAL OF HYPERTENSION
    59. Zusman, RM
      Are there differences among angiotensin receptor blockers?

      AMERICAN JOURNAL OF HYPERTENSION
    60. Chung, O; Unger, T
      Angiotensin II receptor blockade and end-organ protection

      AMERICAN JOURNAL OF HYPERTENSION
    61. Hope, S; Brecher, P; Chobanian, AV
      Comparison of the effects of AT(1) receptor blockade and angiotensin converting enzyme inhibition on atherosclerosis

      AMERICAN JOURNAL OF HYPERTENSION
    62. Sega, R
      Efficacy and safety of eprosartan in severe hypertension

      BLOOD PRESSURE
    63. Sica, DA; Hollenberg, NK
      The renal profile of eprosartan

      PHARMACOTHERAPY
    64. Schuijt, MP; de Vries, R; Saxena, PR; Danser, AHJ
      No vasoactive role of the angiotensin II type 2 receptor in normotensive Wistar rats

      JOURNAL OF HYPERTENSION
    65. Luno, J; de Vinuesa, SG
      Treatment of hypertension: an up to date

      NEFROLOGIA
    66. Fortuno, A; Muniz, P; Ravassa, S; Rodriguez, JA; Fortuno, MA; Zalba, G; Diez, J
      Torasemide inhibits angiotensin II-induced vasoconstriction and intracellular calcium increase in the aorta of spontaneously hypertensive rats

      HYPERTENSION
    67. Morsing, P; Adler, G; Brandt-Eliasson, U; Karp, L; Ohlson, K; Renberg, L; Sjoquist, PO; Abrahamsson, T
      Mechanistic differences of various AT(1)-receptor blockers in isolated vessels of different origin

      HYPERTENSION
    68. Mazzolai, L; Maillard, M; Rossat, J; Nussberger, J; Brunner, HR; Burnier, M
      Angiotensin II receptor blockade in normotensive subjects - A direct comparison of three AT(1) receptor antagonists

      HYPERTENSION
    69. Lim, PO; Nys, M; Naas, AAO; Struthers, AD; Osbakken, M; MacDonald, TM
      Irbesartan reduces QT dispersion in hypertensive individuals

      HYPERTENSION
    70. Ambrose, J; Pribnow, DG; Giraud, FD; Perkins, KD; Muldoon, L; Greenberg, BH
      Angiotensin type 1 receptor antagonism with irbesartan inhibits ventricular hypertrophy and improves diastolic function in the remodeling post-myocardial infarction ventricle

      JOURNAL OF CARDIOVASCULAR PHARMACOLOGY
    71. Mangold, B; Gielsdorf, W; Marino, MR
      Irbesartan does not affect the steady-state pharmacodynamics and pharmacokinetics of warfarin

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    72. Hines, J; Fluharty, SJ; Sakai, RR
      The angiotensin AT(1) receptor antagonist irbesartan has near-peptide affinity and potently blocks receptor signaling

      EUROPEAN JOURNAL OF PHARMACOLOGY
    73. Culman, J; von Heyer, C; Piepenburg, B; Rascher, W; Unger, T
      Effects of systemic treatment with irbesartan and losartan on central responses to angiotensin II in conscious, normotensive rats

      EUROPEAN JOURNAL OF PHARMACOLOGY
    74. Luno, J; de Vinuesa, SG
      Current issues in anti-hypertensive drug therapy

      REVISTA CLINICA ESPANOLA
    75. Brabant, SM; Bertrand, M; Eyraud, D; Darmon, PL; Coriat, P
      The hemodynamic effects of anesthetic induction in vascular surgical patients chronically treated with angiotensin II receptor antagonists

      ANESTHESIA AND ANALGESIA
    76. Brabant, SM; Eyraud, D; Bertrand, M; Coriat, P
      Refractory hypotension after induction of anesthesia in a patient chronically treated with angiotensin receptor antagonists

      ANESTHESIA AND ANALGESIA
    77. de Leeuw, PW
      How do angiotensin II receptor antagonists affect blood pressure?

      AMERICAN JOURNAL OF CARDIOLOGY
    78. Unger, T
      Significance of angiotensin type 1 receptor blockade: Why are angiotensin II receptor blockers different?

      AMERICAN JOURNAL OF CARDIOLOGY
    79. WOLF G; SCHNEIDER A; HELMCHEN U; STAHL RAK
      AT(1)-RECEPTOR ANTAGONISTS ABOLISH GLOMERULAR MCP-1 EXPRESSION IN A MODEL OF MESANGIAL PROLIFERATIVE GLOMERULONEPHRITIS

      Experimental nephrology
    80. MIMRAN A; RUILOPE L; KERWIN L; NYS M; OWENS D; KASSLERTAUB K; OSBAKKEN M
      A RANDOMIZED, DOUBLE-BLIND COMPARISON OF THE ANGIOTENSIN-II RECEPTOR ANTAGONIST, IRBESARTAN, WITH THE FULL DOSE RANGE OF ENALAPRIL FOR THE TREATMENT OF MILD-TO-MODERATE HYPERTENSION

      Journal of human hypertension
    81. KASSLERTAUB K; LITTLEJOHN T; ELLIOTT W; RUDDY T; ADLER E
      COMPARATIVE EFFICACY OF 2 ANGIOTENSIN-II RECEPTOR ANTAGONISTS, IRBESARTAN AND LOSARTAN, IN MILD-TO-MODERATE HYPERTENSION

      American journal of hypertension
    82. POOL JL; GUTHRIE RM; LITTLEJOHN TW; RASKIN P; SHEPHARD AMM; WEBER MA; WEIR MR; WILSON TW; WRIGHT J; KASSLERTAUB KB; REEVES RA
      DOSE-RELATED ANTIHYPERTENSIVE EFFECTS OF IRBESARTAN IN PATIENTS WITH MILD-TO-MODERATE HYPERTENSION

      American journal of hypertension
    83. Vachharajani, NN; Shyu, WC; Smith, RA; Greene, DS
      The effects of age and gender on the pharmacokinetics of irbesartan

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    84. Unger, T; Culman, J; Gohlke, P
      Angiotensin II receptor blockade and end-organ protection: pharmacologicalrationale and evidence

      JOURNAL OF HYPERTENSION
    85. Waeber, B; Brunner, HR
      A look through the new therapeutic window: irbesartan

      JOURNAL OF HYPERTENSION
    86. Kahan, T
      The importance of left ventricular hypertrophy in human hypertension

      JOURNAL OF HYPERTENSION
    87. REEVES RA; LIN CS; KASSLERTAUB K; POULEUR H
      DOSE-RELATED EFFICACY OF IRBESARTAN FOR HYPERTENSION - AN INTEGRATED ANALYSIS

      Hypertension
    88. SCHMITT F; MARTINEZ F; BRILLET G; NGUYENKHOA T; BROUARD R; SISSMANN J; LACOUR B; GRUNFELD JP
      ACUTE RENAL EFFECTS OF AT(1)-RECEPTOR BLOCKADE AFTER EXOGENOUS ANGIOTENSIN-II INFUSION IN HEALTHY-SUBJECTS

      Journal of cardiovascular pharmacology
    89. OPARIL S; GUTHRIE R; LEWIN AJ; MARBURY T; REILLY K; TRISCARI J; WITCHER JA
      AN ELECTIVE-TITRATION STUDY OF THE COMPARATIVE EFFECTIVENESS OF 2 ANGIOTENSIN-II RECEPTOR BLOCKERS, IRBESARTAN AND LOSARTAN

      Clinical therapeutics
    90. POLIDORI C; CICCOCIOPPO R; NISATO D; CAZAUBON C; MASSI M
      EVALUATION OF THE ABILITY OF IRBESARTAN TO CROSS THE BLOOD-BRAIN-BARRIER FOLLOWING ACUTE INTRAGASTRIC TREATMENT

      European journal of pharmacology
    91. CHANG SY; WHIGAN DB; VACHHARAJANI NN; PATEL R
      HIGH-PERFORMANCE LIQUID-CHROMATOGRAPHIC ASSAY FOR THE QUANTITATION OFIRBESARTAN (SR-47436 BMS-186295) IN HUMAN PLASMA AND URINE

      Journal of chromatography B. Biomedical sciences and applications
    92. JOHNSTON CI; RISVANIS J
      PRECLINICAL PHARMACOLOGY OF ANGIOTENSIN-II RECEPTOR ANTAGONISTS - UPDATE AND OUTSTANDING ISSUES

      American journal of hypertension
    93. BRUNNER HR
      THE NEW ANGIOTENSIN-II RECEPTOR ANTAGONIST, IRBESARTAN - PHARMACOKINETIC AND PHARMACODYNAMIC CONSIDERATIONS

      American journal of hypertension
    94. POULEUR HG
      CLINICAL OVERVIEW OF IRBESARTAN - A NEW ANGIOTENSIN-II RECEPTOR ANTAGONIST

      American journal of hypertension
    95. RUILOPE LM
      RENOPROTECTION AND RENIN-ANGIOTENSIN SYSTEM BLOCKADE IN DIABETES-MELLITUS

      American journal of hypertension
    96. FOGARI R; AMBROSOLI S; CORRADI L; ESPOSTI ED; MOS L; NAMI R; NICROSINI F; PESSINA AC; SALVETTI A; VACCARELLA A; ZANCHETTI A; MARTIN A; REEVES RA
      24-HOUR BLOOD-PRESSURE CONTROL BY ONCE-DAILY ADMINISTRATION OF IRBESARTAN ASSESSED BY AMBULATORY BLOOD-PRESSURE MONITORING

      Journal of hypertension
    97. JOHNSTON CI; NAITOH M; BURRELL LM
      RATIONALE AND PHARMACOLOGY OF ANGIOTENSIN-II RECEPTOR ANTAGONISTS - CURRENT STATUS AND FUTURE-ISSUES

      Journal of hypertension
    98. HOLLENBERG NK
      NON-INSULIN-DEPENDENT DIABETES-MELLITUS, NEPHROPATHY, AND THE RENIN SYSTEM

      Journal of hypertension
    99. RUILOPE L
      HUMAN PHARMACOKINETIC PHARMACODYNAMIC PROFILE OF IRBESARTAN - A NEW POTENT ANGIOTENSIN-II RECEPTOR ANTAGONIST/

      Journal of hypertension
    100. ZANCHETTI A
      24-HOUR AMBULATORY BLOOD-PRESSURE EVALUATION OF ANTIHYPERTENSIVE AGENTS

      Journal of hypertension


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 06/06/20 alle ore 11:23:57